The expression of EVs derived from immune cells, granulocytes (CD66b+; Figure 4F) and leukocytes (CD45+; Figure 4G), also increased over time in both TIA and AIS patients, indicating a sustained activation of these cell types on the short-term following the start of pharmacotherapy. This evidence concerns the gene PTPRC and transient ischemic attack.